Unphosphorylated STAT3 modulates alpha7 nicotinic receptor signaling and cytokine production in sepsis

The role of STAT3 in infectious diseases remains undetermined, in part because unphosphorylated STAT3 has been considered an inactive protein. Here, we report that unphosphorylated STAT3 contributes to cholinergic anti‐inflammation, prevents systemic inflammation, and improves survival in sepsis. Bacterial endotoxin induced STAT3 tyrosine phosphorylation in macrophages. Both alpha7 nicotinic receptor (alpha7nAChR) activation and inhibition of JAK2 blunt STAT3 phosphorylation. Inhibition of STAT3 phosphorylation mimicked the alpha7nAChR signaling, inhibiting NF‐κB and cytokine production in macrophages. Transfection of macrophages with the dominant‐negative mutant STAT3F, to prevent its tyrosine phosphorylation, reduced TNF production but did not prevent the alpha7nAChR signaling. However, inhibition of STAT3 protein expression enhanced cytokine production and abrogated alpha7nAChR signaling. Alpha7nAChR controls TNF production in macrophages through a mechanism that requires STAT3 protein expression, but not its tyrosine phosphorylation. In vivo, inhibition of STAT3 tyrosine phosphorylation by stattic prevented systemic inflammation and improved survival in experimental sepsis. Stattic also prevented the production of late mediators of sepsis and improved survival in established sepsis. These results reveal the immunological implications of tyrosine‐unphosphorylated STAT3 in infectious diseases.

[1]  E. Deitch,et al.  JAK2 inhibition prevents innate immune responses and rescues animals from sepsis , 2010, Journal of Molecular Medicine.

[2]  E. Deitch,et al.  Scientific and clinical challenges in sepsis. , 2009, Current pharmaceutical design.

[3]  Hua Yu,et al.  Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. , 2009, Cancer cell.

[4]  M. West,et al.  Does Splenectomy Protect Against Immune-Mediated Complications in Blunt Trauma Patients? , 2009, Molecular medicine.

[5]  S. Akira,et al.  Bacterial Endotoxin Induces the Release of High Mobility Group Box 1 via the IFN-β Signaling Pathway1 , 2009, The Journal of Immunology.

[6]  G. Stark,et al.  Roles of unphosphorylated STATs in signaling , 2008, Cell Research.

[7]  D. Angus Caring for the Critically Ill PatientChallenges and Opportunities , 2007 .

[8]  G. Stark,et al.  Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. , 2007, Genes & development.

[9]  H. Yin,et al.  ROLE OF JANUS KINASE/SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION PATHWAY IN REGULATION OF EXPRESSION AND INFLAMMATION-PROMOTING ACTIVITY OF HIGH MOBILITY GROUP BOX PROTEIN 1 IN RAT PERITONEAL MACROPHAGES , 2007, Shock.

[10]  J. McMurray A new small-molecule Stat3 inhibitor. , 2006, Chemistry & biology.

[11]  Bianca Sperl,et al.  Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. , 2006, Chemistry & biology.

[12]  L. Ulloa,et al.  High-mobility group box 1 (HMGB1) protein: friend and foe. , 2006, Cytokine & growth factor reviews.

[13]  V. Pavlov,et al.  Splenectomy inactivates the cholinergic antiinflammatory pathway during lethal endotoxemia and polymicrobial sepsis , 2006, The Journal of experimental medicine.

[14]  Haichao Wang,et al.  Role of HMGB1 in cardiovascular diseases. , 2006, Current opinion in pharmacology.

[15]  W. Parrish,et al.  HMGB-1 AS A THERAPEUTIC TARGET FOR INFECTIOUS AND INFLAMMATORY DISORDERS , 2006, Shock.

[16]  H. Berthoud,et al.  Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway , 2005, Nature Immunology.

[17]  L. Ulloa The vagus nerve and the nicotinic anti-inflammatory pathway , 2005, Nature Reviews Drug Discovery.

[18]  Kevin J. Tracey,et al.  High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal , 2005, Nature Reviews Immunology.

[19]  K. Tracey,et al.  The "cytokine profile": a code for sepsis. , 2005, Trends in molecular medicine.

[20]  K. Tracey,et al.  Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis , 2004, Nature Medicine.

[21]  C. Dinarello Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. , 2004, Current opinion in pharmacology.

[22]  H. Suh,et al.  Therapeutic effects of lysophosphatidylcholine in experimental sepsis , 2004, Nature Medicine.

[23]  S. Akira,et al.  Aberrant Inflammation and Lethality to Septic Peritonitis in Mice Lacking STAT3 in Macrophages and Neutrophils 1 , 2003, The Journal of Immunology.

[24]  Peter A. Ward,et al.  Novel strategies for the treatment of sepsis , 2003, Nature Medicine.

[25]  E. Fikrig,et al.  STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: A critical role of STAT3 in innate immunity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Kevin J. Tracey,et al.  Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation , 2002, Nature.

[27]  M. Feldmann,et al.  Development of anti-TNF therapy for rheumatoid arthritis , 2002, Nature Reviews Immunology.

[28]  G. Clermont,et al.  Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care , 2001, Critical care medicine.

[29]  R. Bucala,et al.  Protection from septic shock by neutralization of macrophage migration inhibitory factor , 2000, Nature Medicine.

[30]  K. Tracey,et al.  HMG-1 as a late mediator of endotoxin lethality in mice. , 1999, Science.

[31]  S. Akira,et al.  Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. , 1999, Immunity.

[32]  Georges E. Grau,et al.  TNF inhibition and sepsis — sounding a cautionary note , 1997, Nature Medicine.

[33]  S. Akira,et al.  Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[34]  T. Hirano,et al.  A central role for Stat3 in IL‐6‐induced regulation of growth and differentiation in M1 leukemia cells. , 1996, The EMBO journal.

[35]  A. Levitzki,et al.  Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor , 1996, Nature.

[36]  L. Moldawer,et al.  BLOCKADE OF TUMOR NECROSIS FACTOR REDUCES LIPOPOLYSACCHARIDE LETHALITY, BUT NOT THE LETHALITY OF CECAL LIGATION AND PUNCTURE , 1995, Shock.

[37]  R. Newcombe,et al.  Transdermal nicotine as maintenance therapy for ulcerative colitis. , 1995, The New England journal of medicine.

[38]  D. Remick,et al.  Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. , 1992, Journal of immunology.

[39]  Kevin J. Tracey,et al.  Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia , 1987, Nature.